Search

Your search keyword '"Sokolova, Alexandra O."' showing total 22 results
Start Over Author "Sokolova, Alexandra O."
22 results on '"Sokolova, Alexandra O."'

2. Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer

Author

Orme, Jacob J., Taza, Fadi, De Sarkar, Navonil, Tewari, Alok K., Arsalan Naqvi, Syed, Riaz, Irbaz B., Childs, Daniel S., Omar, Noha, Adra, Nabil, Ashkar, Ryan, Cheng, Heather H., Schweizer, Michael T., Sokolova, Alexandra O., Agarwal, Neeraj, Barata, Pedro, Sartor, Oliver, Bastos, Diogo, Smaletz, Oren, Berchuck, Jacob E., McClure, Heather, Taplin, Mary-Ellen, Aggarwal, Rahul, Sternberg, Cora N., Vlachostergios, Panagiotis J., Alva, Ajjai S., Mehra, Niven, Nelson, Peter S., Hwang, Justin, Dehm, Scott M., Shi, Qian, Fleischmann, Zoe, Sokol, Ethan S., Elliott, Andrew, Huang, Haojie, Bryce, Alan, Marshall, Catherine H., and Antonarakis, Emmanuel S.

Published
2024
Full Text
View/download PDF

6. Germline Testing in Prostate Cancer: When and Who to Test

Author

Sokolova, Alexandra O., Cheng, Heather H., and Gong, Jun

Subjects
Oncology, Experimental, Medical tests, Prostate cancer -- Drug therapy, Cancer -- Care and treatment -- Genetic aspects -- Research, Drug approval, Health, National Comprehensive Cancer Network
Abstract

The results of multiple studies have shown that a substantial proportion of men with advanced prostate cancer carry germline DNA repair mutations. Germline testing in prostate cancer may inform treatment decisions and consideration for clinical trials. There are 2 FDA approved PARP inhibitors (PARPi), olaparib (Lynparza) and rucaparib (Rubraca), for the treatment of advanced prostate cancer with DNA repair deficiency. Increasing demand for germline testing in prostate cancer and a shortage of genetic counselors have created a need for alternative care models and encouraged oncologists to take a more active role in performing germline testing. This article summarizes recommendations for germline testing in prostate cancer and describes care models for providing counseling and testing., Introduction Genetic testing in men with prostate cancer has become more widespread since the discovery that men with metastatic prostate cancer are more likely to carry germline DNA repair gene [...]

Published
2021

7. Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer

Author

Orme, Jacob J., primary, Taza, Fadi, additional, De Sarkar, Navonil, additional, Tewari, Alok K., additional, Arsalan Naqvi, Syed, additional, Riaz, Irbaz B., additional, Childs, Daniel S., additional, Omar, Noha, additional, Adra, Nabil, additional, Ashkar, Ryan, additional, Cheng, Heather H., additional, Schweizer, Michael T., additional, Sokolova, Alexandra O., additional, Agarwal, Neeraj, additional, Barata, Pedro, additional, Sartor, Oliver, additional, Bastos, Diogo, additional, Smaletz, Oren, additional, Berchuck, Jacob E., additional, McClure, Heather, additional, Taplin, Mary-Ellen, additional, Aggarwal, Rahul, additional, Sternberg, Cora N., additional, Vlachostergios, Panagiotis J., additional, Alva, Ajjai S., additional, Mehra, Niven, additional, Nelson, Peter S., additional, Hwang, Justin, additional, Dehm, Scott M., additional, Shi, Qian, additional, Fleischmann, Zoe, additional, Sokol, Ethan S., additional, Elliott, Andrew, additional, Huang, Haojie, additional, Bryce, Alan, additional, Marshall, Catherine H., additional, and Antonarakis, Emmanuel S., additional

Published
2023
Full Text
View/download PDF

8. Mixed Adenosquamous Cell Carcinoma of the Prostate with Paired Sequencing on the Primary and Liver Metastasis.

Author

Oyogoa, Emmanuella, Sonpatki, Maya, Brinkerhoff, Brian T., Andeen, Nicole, Meyer, Haley, Ryan, Christopher, and Sokolova, Alexandra O.

Subjects
PROSTATE cancer, PROSTATE-specific membrane antigen, LIVER metastasis, ANDROGEN receptors, PROSTATE, ANDROGEN deprivation therapy
Abstract

This report aims to shed light on the intricate challenges encountered during the diagnosis and treatment of an uncommon variant of prostate cancer—mixed adenosquamous cell carcinoma of the prostate. Prostate cancers of this nature pose distinctive diagnostic and therapeutic dilemmas due to their rarity and complex histological composition. We present a case of a 63-year-old man with metastatic prostate cancer, featuring adenocarcinoma with squamous cell differentiation, who underwent a multimodal treatment approach. The patient responded to first-line carboplatin, docetaxel, and androgen deprivation therapy, followed by androgen receptor pathway inhibitor (ARPI) maintenance. However, disease progression led to radiation therapy and a subsequent switch to Lutetium (177Lu) vipivotide tetraxetan after chemotherapy challenges. Comprehensive genetic profiling revealed shared mutations in the prostate and liver lesions, emphasizing the role of targeted therapies. Prostate-specific membrane antigen (PSMA)-targeted therapy resulted in a notable PSA decline. This case highlights the evolving treatment landscape for rare prostate cancers, integrating genetic insights for tailored interventions. In conclusion, squamous cell carcinoma (SCC) of the prostate is rare, emphasizing the imperative for enhanced comprehension in diagnosis and management. Our case suggests the potential efficacy of ARPI and PSMA-targeted therapies. Our findings advocate for a more nuanced approach to the management of this rare prostate cancer variant, leveraging genomic insights for personalized treatment strategies. This exploration serves as a foundation for further research and clinical considerations in addressing the challenges posed by mixed adenosquamous cell carcinoma of the prostate. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer

Author

Taza, Fadi, Holler, Albert E., Fu, Wei, Wang, Hao, Adra, Nabil, Albany, Costantine, Ashkar, Ryan, Cheng, Heather H., Sokolova, Alexandra O., Agarwal, Neeraj, Kessel, Adam, Bryce, Alan, Nafissi, Nellie, Barata, Pedro, Sartor, A. Oliver, Bastos, Diogo, Smaletz, Oren, Berchuck, Jacob E., Taplin, Mary-Ellen, Aggarwal, Rahul, Sternberg, Cora N., Vlachostergios, Panagiotis J., Alva, Ajjai S., Su, Christopher, Marshall, Catherine H., and Antonarakis, Emmanuel S.

Published
2021
Full Text
View/download PDF

12. Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations

Author

Sokolova, Alexandra O., primary, Marshall, Catherine H., additional, Lozano, Rebeca, additional, Gulati, Roman, additional, Ledet, Elisa M., additional, De Sarkar, Navonil, additional, Grivas, Petros, additional, Higano, Celestia S., additional, Montgomery, Bruce, additional, Nelson, Peter S., additional, Olmos, David, additional, Sokolov, Vadim, additional, Schweizer, Michael T., additional, Yezefski, Todd A., additional, Yu, Evan Y., additional, Paller, Channing J., additional, Sartor, Oliver, additional, Castro, Elena, additional, Antonarakis, Emmanuel S., additional, and Cheng, Heather H., additional

Published
2021
Full Text
View/download PDF

13. Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer

Author

Ledet, Elisa M., primary, Burgess, Earle F., additional, Sokolova, Alexandra O., additional, Jaeger, Ellen B., additional, Hatton, Whitley, additional, Moses, Marcus, additional, Miller, Patrick, additional, Cotogno, Patrick, additional, Layton, Jodi, additional, Barata, Pedro, additional, Lewis, Brian E., additional, Nakazawa, Mari, additional, Zhu, Jason, additional, Dellinger, Beth, additional, Elrefai, Sara, additional, Nafissi, Nellie N., additional, Egan, Jan B., additional, Shore, Neal, additional, McKay, Rana R., additional, Bryce, Alan H., additional, Cheng, Heather H., additional, Antonarakis, Emmanuel S., additional, and Sartor, Oliver, additional

Published
2021
Full Text
View/download PDF

14. Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference

Author

Jensen, Kendal, primary, Konnick, Eric Q., additional, Schweizer, Michael T., additional, Sokolova, Alexandra O., additional, Grivas, Petros, additional, Cheng, Heather H., additional, Klemfuss, Nola M., additional, Beightol, Mallory, additional, Yu, Evan Y., additional, Nelson, Peter S., additional, Montgomery, Bruce, additional, and Pritchard, Colin C., additional

Published
2021
Full Text
View/download PDF

16. Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer

Author

Carlson, Alexander S., primary, Acevedo, Rigo I., additional, Lim, Daniel M., additional, Gulati, Roman, additional, Gawne, Agnes, additional, Sokolova, Alexandra O., additional, Cheng, Heather H., additional, Nelson, Peter S., additional, Montgomery, R. Bruce, additional, Yu, Evan Y., additional, and Schweizer, Michael T., additional

Published
2020
Full Text
View/download PDF

21. Gender Differences in Faculty Rank and Subspecialty Choice among Academic Medical Oncologists.

Author

Graham, Laura S., Sokolova, Alexandra O., Khaki, Ali Raza, Wu, Qian "Vicky", and Davidson, Nancy E.

Subjects
*ONCOLOGISTS, *SEX distribution, *VOCATIONAL guidance, *CERTIFICATION, *TEACHER development, *CROSS-sectional method, *COLLEGE teacher attitudes, *DESCRIPTIVE statistics, *ODDS ratio
Abstract

Gender parity within academic oncology is important. We hypothesized that gender differences exist in subspecialty choice and academic rank among medical oncologists. We performed a cross-sectional study of adult medical oncologists at the top 15 cancer centers. Gender, rank, subspecialty (breast, thoracic, gastrointestinal, and genitourinary) and board certification year were recorded. 570 medical oncologists were identified (60% men; 40% women). More women practice breast oncology (OR 3.1, p < 0.001), but less practice genitourinary oncology (OR 0.37, p < 0.001). 22% of women were full professors vs 34% of men (OR 0.55, p = 0.001). Gender differences persist in academic adult medical oncology. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

22. Co-occurring BRCA2/SPOPMutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-resistant Prostate Cancer

Author

Orme, Jacob J., Taza, Fadi, De Sarkar, Navonil, Tewari, Alok K., Arsalan Naqvi, Syed, Riaz, Irbaz B., Childs, Daniel S., Omar, Noha, Adra, Nabil, Ashkar, Ryan, Cheng, Heather H., Schweizer, Michael T., Sokolova, Alexandra O., Agarwal, Neeraj, Barata, Pedro, Sartor, Oliver, Bastos, Diogo, Smaletz, Oren, Berchuck, Jacob E., McClure, Heather, Taplin, Mary-Ellen, Aggarwal, Rahul, Sternberg, Cora N., Vlachostergios, Panagiotis J., Alva, Ajjai S., Mehra, Niven, Nelson, Peter S., Hwang, Justin, Dehm, Scott M., Shi, Qian, Fleischmann, Zoe, Sokol, Ethan S., Elliott, Andrew, Huang, Haojie, Bryce, Alan, Marshall, Catherine H., and Antonarakis, Emmanuel S.

Abstract

Presence of BRCA2mutations helps identify a subset of patients with prostate cancer who are likely to benefit from poly (ADP-ribose) polymerase (PARP) inhibitors, but additional biomarkers are needed to better refine patient selection. This study found that concurrent SPOPmutations predict enhanced PARP inhibitor sensitivity and durable progression-free survival in BRCA2-altered castration-resistant prostate cancer.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results